-
Sanofi Misses Out on Acquiring Reata Pharmaceuticals to Biogen in USD 7.3 Billion Deal
•
Media outlet Bloomberg reported today that France-based Sanofi (NASDAQ: SNY) lost a bidding war to acquire neurological disease specialist Reata Pharmaceuticals (NASDAQ: RETA) last month. The company was ultimately purchased by US compatriot Biogen (NASDAQ: BIIB) for a substantial USD 7.3 billion. According to unnamed insiders cited by the source,…
-
Sandoz Achieves Primary Endpoint in Phase III Trial for Biosimilar Aflibercept
•
Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz (SWX: SDZ) has announced that a Phase III confirmatory trial for its biosimilar version of Bayer’s (ETR: BAYN) Eylea/Wetlia (aflibercept) has successfully reached its primary efficacy endpoint in neovascular (wet) age-related macular degeneration (nAMD). The study demonstrated that Sandoz’s biosimilar product showed no clinically…
-
Gilead Sciences Enters Collaboration with Tentarix Biotherapeutics for Polyspecific Antibodies
•
Gilead Sciences (NASDAQ: GILD) has announced the initiation of three collaboration programs with US-based Tentarix Biotherapeutics, focusing on the discovery and development of conditional polyspecific antibodies for oncology and inflammatory diseases. The collaboration underscores Gilead’s commitment to advancing innovative treatments in these therapeutic areas. Financial Terms and Acquisition RightsUnder the…
-
Amoy Diagnostics and AstraZeneca Expand Collaboration on Companion Diagnostic Development
•
China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has announced a new cooperation agreement with UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN), focusing on the development of a companion diagnostic (CDx). This collaboration builds upon a global strategic master collaboration agreement that was first signed at the end of 2021.…
-
Everest Medicines’ Partner Venatorx Pharmaceuticals Receives FDA Priority Review for Cefepime-Taniborbactam
•
China-based Everest Medicines (HKG: 1952) announced that its partner, Venatorx Pharmaceuticals, has received acceptance from the US Food and Drug Administration (FDA) for a New Drug Application (NDA) for cefepime-taniborbactam, an investigational beta-lactam/beta-lactamase inhibitor (BL/BLI) antibiotic. The drug is intended for the potential treatment of adult patients with complicated urinary…
-
CStone Pharmaceuticals Reports 2023 Interim Financials and Business Milestones
•
China-based CStone Pharmaceuticals (HKG: 2616) has announced its 2023 interim financial results alongside key business highlights. The company reported total revenues of RMB 261.5 million (USD 40 million) for the six months ended June 30, 2023, with pharmaceutical product sales contributing RMB 246.9 million (USD 34 million), marking a 53%…
-
HitGen Inc. Partners with Nested Therapeutics for Precision Medicine Research
•
China-based HitGen Inc. (SHA: 688222) has announced a research service agreement with Cambridge, Massachusetts-based precision medicine biotech Nested Therapeutics, Inc. Under the agreement, HitGen will leverage its DNA-encoded library (DEL) technology platform to identify hits against targets of interest for Nested. This collaboration combines HitGen’s expertise in DEL technology with…
